Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.18 SEK | +16.46% | +13.97% | +70.17% |
Apr. 18 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
Apr. 12 | Recruitment Milestone Reaches in Diamyd® Phase 3 Trial | CI |
Sales 2024 * | 3M 276K | Sales 2025 * | 3M 276K | Capitalization | 1.15B 106M |
---|---|---|---|---|---|
Net income 2024 * | -133M -12.24M | Net income 2025 * | -165M -15.18M | EV / Sales 2024 * | 353 x |
Net cash position 2024 * | 87M 8.01M | Net cash position 2025 * | 128M 11.78M | EV / Sales 2025 * | 340 x |
P/E ratio 2024 * |
-7.99
x | P/E ratio 2025 * |
-6.43
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.91% |
Latest transcript on Diamyd Medical AB
1 day | +16.46% | ||
1 week | +13.97% | ||
Current month | +6.68% | ||
1 month | +2.01% | ||
3 months | +36.34% | ||
6 months | +62.26% | ||
Current year | +70.17% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 16-04-09 |
Founder | 83 | 95-12-31 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 09-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 83 | 95-12-31 | |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 52 | 21-04-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 11.18 | +16.46% | 408,939 |
24-04-23 | 9.6 | +3.45% | 62,599 |
24-04-22 | 9.28 | -4.53% | 150,865 |
24-04-19 | 9.72 | -0.82% | 110,395 |
24-04-18 | 9.8 | -0.10% | 137,623 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 11:29 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+70.17% | 105M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- DMYD B Stock